Orthocell Limited (ASX:OCC)
Australia · Delayed Price · Currency is AUD | Market Cap | 143.01M -56.6% |
| Revenue (ttm) | 11.41M +45.4% |
| Net Income | -13.91M |
| EPS | -0.05 |
| Shares Out | 272.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,498,872 |
| Open | 0.5950 |
| Previous Close | 0.6000 |
| Day's Range | 0.5100 - 0.6000 |
| 52-Week Range | 0.5100 - 1.3000 |
| Beta | -0.03 |
| Analysts | Strong Buy |
| Price Target | 1.14 (+117.14%) |
| Earnings Date | Oct 22, 2026 |
About Orthocell
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen sc... [Read more]
Financial Performance
In fiscal year 2026, Orthocell's revenue was 11.41 million, an increase of 45.37% compared to the previous year's 7.85 million. Losses were -13.91 million, 62.4% more than in 2025.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for OCC stock is "Strong Buy." The 12-month stock price target is $1.14, which is an increase of 117.14% from the latest price.
News
Orthocell Earnings Call Transcript: Q1 2027
Remplir U.S. sales rose 21% QoQ and units 25%, while distributor coverage reached 70% of the population. AUD 39 million in cash supports commercialization and capacity expansion; management expects material growth in coming quarters.
Orthocell Earnings release: Q1 2027
Orthocell released its Q1 2027 earnings on October 21, 2026, summarizing the period's financial results.
Orthocell Slides: Q1 2027
Orthocell has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on October 21, 2026.
Orthocell Annual report: H2 2026
Orthocell has published its H2 2026 annual report on August 30, 2026.
Orthocell Earnings release: Q4 2026
Orthocell released its Q4 2026 earnings on July 13, 2026, summarizing the period's financial results.
Orthocell Slides: Q4 2026
Orthocell has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 13, 2026.
Orthocell Earnings release: Q3 2026
Orthocell released its Q3 2026 earnings on April 19, 2026, summarizing the period's financial results.
Orthocell Slides: Q3 2026
Orthocell has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 19, 2026.
Orthocell Gets Approval To Sell Remplir To The U.S. Department Of Defence Hospital Network
(RTTNews) - Orthocell Ltd. (OCC.AX), a regenerative medicine company announced that it has approval for its Remplir nerve repair device to be used across the 51 United States Department of Defence and...
Orthocell Slides: Investor presentation
Orthocell has posted slides in relation to its latest quarterly earnings report, which was published on March 30, 2026.
Orthocell Quarterly report: H1 2026
Orthocell has published its H1 2026 quarterly earnings report on February 23, 2026.
Orthocell Slides: Investor presentation
Orthocell has posted slides in relation to its latest quarterly earnings report, which was published on February 1, 2026.
Orthocell Earnings release: Q2 2026
Orthocell released its Q2 2026 earnings on January 18, 2026, summarizing the period's financial results.
The company repairing human bone with Kimberley pearl shells
Perth-based Orthocell has increased its stake in a local biomedical company producing bone repair products made from West Australian pearl shells.
Orthocell Slides: FY 2025
Orthocell has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 5, 2025.
Perth biotech Orthocell targets US growth with $25m capital injection
New shares were being offered at $1.30 per share – a 9.1 per cent discount to the last trading price via sole lead manager Canaccord Genuity.
Perth’s billionaire set is piling into this little-known medtech
The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break into the US.